10-Q: ProMIS Neurosciences Reports Q2 Loss, Secures $21.6M Funding

ProMIS Neurosciences reported increased net losses and negative working capital for Q2 2025, but subsequently secured $21.6 million in gross proceeds to support ongoing operations and clinical trials.

Summary

• Net loss for the three months ended June 30, 2025, was $10.1 million, compared to $2.6 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $17.5 million, compared to $6.3 million for the same period in 2024.
• Research and development expenses increased by 284% to $14.2 million for the six months ended June 30, 2025, primarily due to the PMN310 Phase 1b clinical trial.
• Cash balance as of June 30, 2025, was $4.5 million, a decrease from $13.3 million at December 31, 2024.
• Accumulated deficit reached $108.2 million as of June 30, 2025.
• Subsequent to the quarter, in July 2025, the company raised aggregate gross proceeds of $21.6 million through a registered direct offering, private placements, and discounted warrant exercises.
• PMN310, the lead product candidate for Alzheimer's disease, received FDA Fast Track Designation on July 21, 2025.
• Enrollment for the PMN310 Phase 1b PRECISE-AD trial is over 50% complete, with no observed cases of ARIA (amyloid-related imaging abnormalities) to date.

Sentiment

Score: 4

Explanation: While the company reported significantly increased losses and a going concern warning for the period, the subsequent successful capital raise of $21.6 million and the FDA Fast Track Designation for its lead candidate PMN310 provide a crucial lifeline and positive clinical momentum. The material weakness in internal controls and continued heavy cash burn remain significant concerns, but the recent funding mitigates immediate liquidity risk, preventing a lower score.

Positives

• Successfully completed Phase 1a and commenced Phase 1b (PRECISE-AD) clinical trial for PMN310 in Alzheimer's disease.
• FDA granted Fast Track Designation to PMN310 on July 21, 2025, recognizing its potential to address an unmet medical need.
• Enrollment for the PMN310 Phase 1b trial is progressing well, with over 50% of planned patients enrolled.
• No cases of ARIA (brain swelling or microhemorrhages) observed in the PMN310 trial to date, supporting its non-plaque binding mechanism.
• Secured significant post-period funding of $21.6 million in July 2025 from various equity transactions, improving immediate liquidity.
• PMN267 (ALS) and PMN442 (MSA) candidates are humanized and ready for IND-enabling studies, subject to resources.

Negatives

• Net loss significantly increased to $17.5 million for the six months ended June 30, 2025, from $6.3 million in the prior year period.
• Cash balance decreased to $4.5 million as of June 30, 2025, from $13.3 million at December 31, 2024, indicating substantial cash burn.
• Accumulated deficit grew to $108.2 million as of June 30, 2025.
• Negative working capital of ($314,591) as of June 30, 2025.
• Management believes conditions raise substantial doubt about the company's ability to continue as a going concern within the next twelve months from the filing date, despite recent funding.
• Identified a material weakness in internal control over financial reporting related to insufficient review controls over fair value calculations.

Risks

• Substantial doubt about the ability to continue as a going concern for the full one-year period following the filing date.
• Requirement for additional financing to achieve goals, with no assurance of obtaining necessary capital on acceptable terms or at all.
• Failure to raise capital could force delays, reductions, or termination of development programs, commercialization efforts, or other operations.
• Inability to develop and maintain an effective system of internal control over financial reporting due to a material weakness, potentially affecting accurate and timely financial reporting.
• Potential adverse effects on business from substantial changes to U.S. fiscal, tax, and other federal policies, including new tariffs and tax laws like the OBBBA signed July 4, 2025.
• Uncertainty of clinical trial outcomes, making it difficult to estimate future expenses or predict profitability.
• Dependence on successful development, regulatory approvals, and eventual licensing/commercialization of product candidates to generate revenue.

Future Outlook

The company expects to incur net losses for at least the next several years as it advances product candidates through development and clinical trials. Research and development expenses, general and administrative expenses, and capital expenditures are expected to increase with further funding. Six-month interim data from the PMN310 Phase 1b study is anticipated in Q2 2026, with topline results expected in Q4 2026.

Management Comments

• Management believes these conditions raise substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the date these unaudited condensed consolidated financial statements are issued.
• We expect to incur net losses for at least the next several years as the Company advances its product candidates.
• We are actively pursuing additional financing to further develop certain of the Company’s scientific initiatives, but there is no assurance these initiatives will be successful, timely or sufficient.
• We have not observed any cases of ARIA, including brain swelling or microhemorrhages [in the PMN310 Phase 1b trial].
• We anticipate reporting six-month interim data from the [PMN310 Phase 1b] study in the second quarter of 2026, with topline results expected in the fourth quarter of 2026.

Industry Context

ProMIS Neurosciences operates in the highly capital-intensive neurodegenerative disease drug development sector, focusing on protein-misfolding diseases like Alzheimer's, ALS, and MSA. The company's strategy of selectively targeting misfolded toxic proteins aims to differentiate its candidates from broader approaches. The FDA Fast Track Designation for PMN310 highlights the significant unmet medical need in Alzheimer's disease, a common theme in the industry. The reliance on external financing and the 'going concern' warning are typical challenges for clinical-stage biotech companies that have not yet generated product revenue.

Comparison to Industry Standards

• The company's focus on selectively targeting misfolded proteins (e.g., amyloid-beta oligomers for AD, TDP-43 for ALS, alpha-synuclein for MSA) represents a targeted approach compared to some broader amyloid-beta targeting therapies that have faced challenges with ARIA. The reported absence of ARIA in PMN310's Phase 1b trial to date is a positive indicator in this context.
• The FDA Fast Track Designation for PMN310 aligns with the industry's push for accelerated development of therapies for serious conditions with unmet needs, similar to designations granted to other promising AD candidates.
• The significant increase in R&D expenses is consistent with a clinical-stage biotech company advancing its lead candidate (PMN310) into Phase 1b, a common expenditure pattern in the pharmaceutical industry.
• The 'going concern' warning and reliance on capital raises are standard for pre-revenue biopharmaceutical companies, though the magnitude of the accumulated deficit and cash burn underscores the high financial risk inherent in this sector.

Corporate Governance

Related Party Transactions

• UBC Collaborative Research Agreement: Extended through February 2026 with aggregate funding increased to C$5,830,000. The company's Chief Scientific Officer is a principal investigator at UBC.
• UBC Agreement (License): Annual license fee of C$25,000 payable for technology development and commercialization, with potential royalty payments based on revenue from licensed technology.

Stakeholder Impact

• Shareholders: Significant dilution risk from ongoing and future equity financings. Increased losses and going concern warning create uncertainty, but recent capital raise provides a temporary buffer. Clinical trial progress and Fast Track designation offer potential upside.
• Employees: Increased employee salaries and benefits, and share-based compensation, indicate continued investment in human capital. Severance costs suggest some personnel adjustments.
• Customers/Patients: Potential for new therapeutic options for neurodegenerative diseases (Alzheimer's, ALS, MSA) if product candidates are successfully developed and approved.
• Creditors: The 'going concern' warning indicates elevated risk, but the recent capital raise improves short-term liquidity.
• Suppliers/CROs: Increased R&D expenses, particularly for the PMN310 trial, suggest continued engagement and payments to contract research organizations and consultants.

Next Steps

• Continue advancing PMN310 through its Phase 1b PRECISE-AD clinical trial.
• Report six-month interim data from the PMN310 Phase 1b study in Q2 2026.
• Report topline results from the PMN310 Phase 1b study in Q4 2026.
• Progress PMN267 (ALS) and PMN442 (MSA) to IND-enabling studies, subject to sufficient resources.
• Continue development of amyloid vaccine program (PMN311) and alpha-synuclein vaccine (PMN400).
• Update proprietary discovery algorithms with machine learning capabilities.
• Actively pursue additional financing through public/private financings, debt, collaborations, and licensing agreements.
• Remediate the identified material weakness in internal control over financial reporting.

Key Dates

Recommendation

While the company faces significant financial challenges, including increased losses and a 'going concern' warning, the successful post-period capital raise of $21.6 million provides crucial liquidity. The FDA Fast Track Designation for PMN310 and positive early clinical trial progress (no ARIA observed) are strong positive catalysts. However, the company remains pre-revenue, highly speculative, and subject to substantial dilution risk. The identified material weakness in internal controls also adds a layer of operational risk. Given the high risk but also the recent positive developments, a 'hold' recommendation is appropriate for investors willing to tolerate high volatility and monitor future clinical and financial milestones closely.

Keywords

Neurosciences, Alzheimer's Disease, ALS, MSA, PMN310, PMN267, PMN442, Biotechnology, Clinical Trials, Drug Development, Antibody Therapy, SEC Filing, 10-Q, Going Concern, Capital Raise, FDA Fast Track